160 related articles for article (PubMed ID: 36929435)
1. Unraveling family ties in Hodgkin lymphoma.
Fox LC
Blood; 2023 Mar; 141(11):1240-1241. PubMed ID: 36929435
[No Abstract] [Full Text] [Related]
2. Metachronous and clonally related classic Hodgkin lymphoma and nodular lymphocyte predominant Hodgkin lymphoma.
Ding Y; Campbell A; Zhang X; Fu K; Yuan J
Pathology; 2021 Feb; 53(2):285-288. PubMed ID: 32951907
[No Abstract] [Full Text] [Related]
3. Lymphoma of uncertain phenotype.
Zulian GB; Dietrich PY; Conne B; Anchisi S; Pache JC; Rouden C; Alberto P
Ann Oncol; 1995 Oct; 6(8):827-32. PubMed ID: 8589022
[No Abstract] [Full Text] [Related]
4. Familial Hodgkin Lymphoma.
Faizan M; Kashif RUA; Anwar S; Safdar M
J Coll Physicians Surg Pak; 2017 Sep; 27(9):572-573. PubMed ID: 29017675
[TBL] [Abstract][Full Text] [Related]
5. Hematology. Are macrophages the bad guys in Hodgkin lymphoma?
Diehl V
Nat Rev Clin Oncol; 2010 Jun; 7(6):301-2. PubMed ID: 20517336
[TBL] [Abstract][Full Text] [Related]
6. Genetic factors in leukemia and lymphoma.
Ponz de Leon M
Recent Results Cancer Res; 1994; 136():287-305. PubMed ID: 7863101
[No Abstract] [Full Text] [Related]
7. Nodular lymphocyte-predominant Hodgkin lymphoma and T cell histiocyte-rich large B cell lymphoma: diagnosis in two monozygotic twins.
Cano I; Lozano M; Rodríguez A; Mate A; Adrados M; López Mdel M; Carro R; Montes-Moreno S
Histopathology; 2010 Jul; 57(1):159-62. PubMed ID: 20653789
[No Abstract] [Full Text] [Related]
8. Introduction to a review series on Hodgkin lymphoma: change is here.
Sehn LH
Blood; 2018 Apr; 131(15):1629-1630. PubMed ID: 29500172
[No Abstract] [Full Text] [Related]
9. Relapsed nodular sclerosis Hodgkin lymphoma and therapy-related myeloid sarcoma in a mediastinal mass.
Paessler M; Choi J
Blood; 2014 Feb; 123(9):1291. PubMed ID: 24716232
[No Abstract] [Full Text] [Related]
10. XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma.
Advani RH; Hoppe RT
Hematol Oncol; 2015 Jun; 33 Suppl 1():90-5. PubMed ID: 26062064
[No Abstract] [Full Text] [Related]
11. The molecular mechanisms of classic Hodgkin's lymphoma.
Felberbaum RS
Yale J Biol Med; 2005 Jul; 78(4):203-10. PubMed ID: 16720015
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin disease/lymphoma.
Hoppe RT; Advani RH; Ambinder RF; Bierman PJ; Bloomfield CD; Blum K; Dabaja B; Djulbegovic B; Forero A; Gordon LI; Hernandez-Ilizaliturri FJ; Hudson MM; Kaminski MS; Love G; Maloney DG; Mansur D; Mauch PM; Moore JO; Schilder RJ; Weiss LM; Winter JN; Yahalom J; Zelenetz AD;
J Natl Compr Canc Netw; 2008 Jul; 6(6):594-622. PubMed ID: 18597713
[No Abstract] [Full Text] [Related]
13. Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma.
McKay P; Fielding P; Gallop-Evans E; Hall GW; Lambert J; Leach M; Marafioti T; McNamara C;
Br J Haematol; 2016 Jan; 172(1):32-43. PubMed ID: 26538004
[No Abstract] [Full Text] [Related]
14. Unusual sequence of lymphoid disorders: follicular lymphoma subsequent to Hodgkin lymphoma and transformed into diffuse large B-cells non Hodgkin lymphoma.
Niscola P; Palombi M; Fratoni S; Trawinska MM; Scaramucci L; Giovannini M; Perrotti A; De Fabritiis P
Acta Oncol; 2009; 48(7):1073-4. PubMed ID: 19308758
[No Abstract] [Full Text] [Related]
15. Plasma cells in classical Hodgkin lymphoma: a new player in the microenvironment?
Visser L
Br J Haematol; 2019 Jan; 184(2):119-120. PubMed ID: 30485402
[No Abstract] [Full Text] [Related]
16. Genetic associations in classical hodgkin lymphoma: a systematic review and insights into susceptibility mechanisms.
Kushekhar K; van den Berg A; Nolte I; Hepkema B; Visser L; Diepstra A
Cancer Epidemiol Biomarkers Prev; 2014 Dec; 23(12):2737-47. PubMed ID: 25205514
[TBL] [Abstract][Full Text] [Related]
17. [Molecular basis of Hodgkin lymphoma and anaplastic large cell lymphoma and molecular targeting therapy by an NF-kappaB inhibitor].
Horie R
Rinsho Ketsueki; 2007 Apr; 48(4):255-61. PubMed ID: 17515115
[No Abstract] [Full Text] [Related]
18. XVII. Treatment of advanced-stage Hodgkin lymphoma.
Engert A
Hematol Oncol; 2015 Jun; 33 Suppl 1():87-9. PubMed ID: 26062063
[No Abstract] [Full Text] [Related]
19. [Interview with Professor Dr. Volker Diehl, Cologne. Hodgkin disease: on the path to causal therapy? (interview by Christine Vetter)].
Diehl V
MMW Fortschr Med; 2002 Jan; 144(5):8. PubMed ID: 11883038
[No Abstract] [Full Text] [Related]
20. The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases.
Gualco G; Natkunam Y; Bacchi CE
Mod Pathol; 2012 May; 25(5):661-74. PubMed ID: 22222636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
